Altimmune Brings In Two Biotech Veterans As Three Directors Plan To Retire In 2027

Former Aurinia CEO Peter Greenleaf and former Madrigal CFO Alex Howarth join the board November 2, expanding it to eleven seats.

Share
Altimmune Brings In Two Biotech Veterans As Three Directors Plan To Retire In 2027

Altimmune, which is developing a liver-disease drug called pemvidutide, named two biotech veterans to its board on Tuesday: Peter Greenleaf, most recently CEO of Aurinia Pharmaceuticals, and Alex Howarth, most recently CFO of Madrigal Pharmaceuticals. Three sitting directors have said they will retire at the 2027 annual meeting.

Two seats added, three to open

The board voted October 23 to grow from nine to eleven directors. Greenleaf and Howarth take their seats effective November 2.

The same day, directors John Gill, Mitchel Sayare and Klaus Schafer told the board they will not stand for re-election at the 2027 annual meeting. All three stay on until then. The company said their exit is not due to any disagreement over its operations, policies or practices, and described it as a planned transition.

Each new director gets options on 160,000 shares and a $40,000 annual cash retainer under the non-employee director pay policy.

Sucampo sale and $2 billion Akcea deal

Greenleaf, 54, chairs Pelthos Therapeutics. He was CEO and chairman of Sucampo Pharmaceuticals, which the company said he oversaw through a sale for about $1.2 billion. He also held CEO roles at Cerecor and Histogenics.

Howarth, 58, was Madrigal's CFO from May 2021 through May 2024, and the company credits him with more than 30 licensing and M&A deals. Earlier, as chief operating officer of Akcea Therapeutics, he led its sale in a transaction valued at $2 billion.

A late-stage liver drug

Altimmune is a late clinical-stage company with no approved products. Pemvidutide, a weekly injected peptide that targets glucagon and GLP-1 receptors, is being studied in MASH (a serious fatty liver disease), alcohol use disorder and alcohol-associated liver disease. The FDA has granted it Breakthrough Therapy and Fast Track designations for MASH.

CEO and Chairman Jerry Durso said the Phase 3 MASH trial is funded and ongoing, and that Phase 2 alcohol use disorder data were outstanding. "Now is the right time to evolve our Board of Directors," he said.

Howarth said the company's balance sheet offers "significant leverage to support future growth."

Greenleaf and Howarth begin serving November 2, and the company's address changes that same month to 350 Mount Kemble Avenue in Morristown, New Jersey, as of November 1.

Sources